Postoperative Prognostic Predictors of Bile Duct Cancers: Clinical Analysis and Immunoassays of Tissue Microarrays

Background/Aims Cholangiocarcinoma frequently recurs even after curative resection. Expression levels of proteins such as epidermal growth factor receptor (EGFR), Snail, epithelial cadherin (E-cadherin), and interleukin-6 (IL-6) examined by immunohistochemistry have been studied as potential prognostic factors for cholangiocarcinoma. The aim of this study was to investigate significant factors affecting the prognosis of resectable cholangiocarcinoma. Methods Ninety-one patients who underwent surgical resection at Samsung Medical Center for cholangiocarcinoma from 1995 to 2013 were included in this study. Expression levels of E-cadherin, Snail, IL-6, membranous EGFR, and cytoplasmic EGFR were analyzed by immunohistochemistry using tissue microarray blocks made from surgical specimens. Results Patients with high levels of membranous EGFR in tissue microarrays had significantly shorter overall survival (OS) and disease-free survival (DFS) high membranous EGFR (score 0–2) 38.0 months versus low membranous EGFR (score 3) 14.4 months (p=0.008) and high membranous EGFR (score 0–2) 23.2 months versus low membranous EGFR (score 3) 6.1 months (p=0.004), respectively. On the other hand, E-cadherin, Snail, cytoplasmic EGFR, and IL-6 did not show significant association with OS or DFS. Patients with distant metastasis had significantly higher IL-6 levels than those with locoregional recurrence (p=0.01). Conclusions This study showed that overexpression of membranous EGFR was significantly associated with shorter OS and DFS in surgically resected bile duct cancer patients. In addition, higher IL-6 expression was a predictive marker for recurrence in cholangiocarcinoma patients with distant organ metastasis after surgical resection.

[1]  B. Sipos,et al.  Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma , 2020, Journal of gastroenterology and hepatology.

[2]  D. Bethmann,et al.  Prognostic impact of cytoplasmatic EGFR upregulation in patients with oral squamous cell carcinoma: A pilot study , 2020, Molecular and clinical oncology.

[3]  G. Gores,et al.  Emerging molecular therapeutic targets for cholangiocarcinoma. , 2017, Journal of hepatology.

[4]  V. Paradis,et al.  Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. , 2017, Journal of hepatology.

[5]  B. Blechacz.  Cholangiocarcinoma: Current Knowledge and New Developments , 2016, Gut and liver.

[6]  Fei Ma,et al.  Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer. , 2015, Molecular medicine reports.

[7]  B. Han,et al.  Characterization of EGFR family gene aberrations in cholangiocarcinoma. , 2014, Oncology reports.

[8]  Y. Matsuno,et al.  Prognostic significance of epithelial–mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray , 2014, British Journal of Cancer.

[9]  H. Saya,et al.  Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis , 2014, Tumor Biology.

[10]  Chiun Hsu,et al.  Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan , 2014, Journal of gastroenterology and hepatology.

[11]  F. T. ten Kate,et al.  Prognostic Biomarkers in Patients with Resected Cholangiocarcinoma: A Systematic Review and Meta-analysis , 2014, Annals of Surgical Oncology.

[12]  S. Choi,et al.  Prognostic factors following surgical resection of distal bile duct cancer , 2013, Journal of the Korean Surgical Society.

[13]  H. Eguchi,et al.  Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. , 2013, European journal of cancer.

[14]  X. Yao,et al.  Clinicopathological and prognostic significance of epithelial mesenchymal transition-related protein expression in intrahepatic cholangiocarcinoma , 2012, OncoTargets and therapy.

[15]  Jun Liang,et al.  Prognostic significance of snail expression in hilar cholangiocarcinoma , 2012, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[16]  B. Carr,et al.  Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma , 2012, Medical Oncology.

[17]  S. Choi,et al.  Survival benefits of surgical resection in recurrent cholangiocarcinoma , 2011, Journal of the Korean Surgical Society.

[18]  Yasunori Sato,et al.  Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. , 2010, The American journal of pathology.

[19]  Guang-Yaw Liu,et al.  Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma , 2009, Journal of Biomedical Science.

[20]  Yutaka Kawakami,et al.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. , 2009, Cancer cell.

[21]  T. Rikiyama,et al.  Bile acids repress E‐cadherin through the induction of Snail and increase cancer invasiveness in human hepatobiliary carcinoma , 2008, Cancer science.

[22]  E. Lander,et al.  Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. , 2008, Cancer research.

[23]  K. Roepstorff,et al.  Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer , 2008, Histochemistry and Cell Biology.

[24]  S. Hirohashi,et al.  Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma , 2007, British Journal of Cancer.

[25]  T. Patel,et al.  Cholangiocarcinoma: emerging approaches to a challenging cancer , 2007, Current opinion in gastroenterology.

[26]  David L Rimm,et al.  Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome , 2007, Cancer investigation.

[27]  T. Patel,et al.  Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. , 2006, Cancer research.

[28]  T. Venesio,et al.  Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma , 2006, Clinical Cancer Research.

[29]  J. Chung,et al.  Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[30]  H. Stenmark,et al.  Defective downregulation of receptor tyrosine kinases in cancer , 2004, The EMBO journal.

[31]  Hidetaka Mochizuki,et al.  The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness: Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2004, Pancreas.

[32]  Xuelin Huang,et al.  Validation of tissue microarray technology in ovarian carcinoma , 2004, Modern Pathology.

[33]  W. Jarnagin,et al.  Surgical management of cholangiocarcinoma. , 2004, Seminars in liver disease.

[34]  Erik Schrumpf,et al.  Diagnosis and treatment of cholangiocarcinoma , 2004, Current gastroenterology reports.

[35]  D. Trask,et al.  Validation of Tissue Microarrays Using P53 Immunohistochemical Studies of Squamous Cell Carcinoma of the Larynx , 2003, Modern Pathology.

[36]  T. Tammela,et al.  Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma , 2003, British Journal of Cancer.

[37]  Mårten Fernö,et al.  Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. , 2002, Archives of pathology & laboratory medicine.

[38]  D. Heimburger,et al.  Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  Tony Hunter,et al.  Epidermal Growth Factor-Induced Tumor Cell Invasion and Metastasis Initiated by Dephosphorylation and Downregulation of Focal Adhesion Kinase , 2001, Molecular and Cellular Biology.

[40]  O. Kallioniemi,et al.  Tissue microarray technology for high-throughput molecular profiling of cancer. , 2001, Human molecular genetics.

[41]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[42]  J. Lunz,et al.  Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor β1, and activin a: Comparison of a cholangiocarcinoma cell line with primary cultures of non‐neoplastic biliary epithelial cells , 2000, Hepatology.

[43]  James S Goydos,et al.  Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. , 1998, Annals of surgery.

[44]  H. Frierson,et al.  Guardians of the wax ... and the patient. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[45]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[46]  L. Akslen,et al.  Prognostic impact of EGF-receptor in papillary thyroid carcinoma. , 1993, British Journal of Cancer.

[47]  J. Donohue,et al.  Outcomes after curative resections of cholangiocarcinoma. , 1993, Archives of surgery.

[48]  W. Fiers,et al.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role , 1991, Cell.